Replay_Logo_Black_CMYK.png
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
30 avr. 2024 07h00 HE | Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
Replay_Logo_Black_CMYK.png
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
11 mars 2024 07h00 HE | Replay Bio
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed...
Replay_Logo_Black_CMYK.png
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
18 déc. 2023 07h00 HE | Replay Bio
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens Replay and its...
Replay_Logo_Black_CMYK.png
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
21 sept. 2023 08h00 HE | Replay Bio
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform...
Replay_Logo_Black_CMYK.png
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma
20 juin 2023 07h00 HE | Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for sarcoma First-in-human Phase 1 study of NY-ESO-1...
Replay_Logo_Black_CMYK.png
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
28 nov. 2022 07h00 HE | Replay Bio
Replay receives $1.5 million grant for its hypoimmunogenic technology platform Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable cell source hypoimmunogenic...
Replay_Logo_Black_CMYK.png
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases
21 nov. 2022 07h00 HE | Replay Bio
Replay launches big DNA HSV gene therapy company, Telaria, focused on rare skin diseases Second product company using Replay’s next-generation high payload capacity HSV delivery vector developed at...